Sign in
WithdrawnPhase 1

Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)

Key facts

Who runs it
University of California, Davis
Where
Sacramento, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1
Started
Jul 2024
Ended
May 2026
Type of study
Interventional
Treatments tested
  • Aminolevulinic Acid
Record updated
15 August 2024
Why it stopped
PI choice.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Histological confirmation of any subtype of primary Grades 2 or 3 soft tissue sarcomas (STS), per biopsy evaluation by a pathologist, according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
  • Treatment decision includes planned surgical resection of STS
  • Age ≥18 years at time of consent
  • ECOG Performance Status 0 - 1 (see Appendix)
  • Hematology and blood chemistry parameters defined by:; Leukocytes ≥ 3 × 109/L; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L, transfusions may be used to raise platelets to ≥ 100 × 109/L (no washout required); Hemoglobin ≥ 9 g/dL, transfusions may be used to raise Hgb to ≥ 9 g/dL (no washout required); Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); Aspartate transaminase (AST) / alanine transaminase (ALT) ≤ 2.5 × institutional ULN; Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL/min/1.73 m2 for patients with creatinine above institutional ULN
  • Participants of reproductive potential must agree to using adequate contraception (e.g., hormonal or barrier method of birth control; abstinence, an intrauterine device) for the duration of study participation (including dosing interruptions) and up to 42 days after end of study intervention; or be surgically sterilized (e.g., hysterectomy, tubal ligation, or vasectomy)
  • Ability to swallow study agent
  • Ability to understand and willingness to sign an informed consent form
  • Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study

Who cannot take part

  • Uncontrolled, known concurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness
  • Patient has had chemotherapy, tumor resection, or radiation treatment ≤ 21 days prior to surgery
  • Planned use of other potentially phototoxic substances (e.g., St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones and tetracyclines), and topical preparations containing aminolevulinic acid (5-ALA) for 24 hours during the perioperative period (defined as 24 hours prior to surgery to up to 24 hours post surgery)
  • Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial
  • Acute/chronic forms of porphyria
  • Simultaneous participation in another clinical trial ≤ 21 days of enrollment or during the duration of the study period
  • Pregnant or planning to become pregnant during study participation or breastfeeding

Where in United States

  • University of California Davis Comprehensive Cancer CenterSacramento, United States

About the trial

What the trial wants to find out

This will be a prospective pilot study that will evaluate 20 patients who were diagnosed with FNCLCC Grade 2 or 3 soft tissue sarcomas and will undergo surgical resection. Based upon the FDA label, successful protocols used for intraoperative fluorescence-guided visualization for glioma resections, and on drug company current dosing recommendation for this study, patients will be administered 20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgery. The use of 5-ALA fluorescence will be relevant for evaluating the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

The group in the trial

  • Aminolevulinic acid (5-ALA)Treatment being tested

    20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgical resection. 5-ALA fluorescence will be used to evaluate the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.

    Treatment: Aminolevulinic Acid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
15 August 2024